Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia

  • Campo Milán, Marta del|||0000-0003-2808-3699
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Gandy, Sam
  • Onyike, Chiadi U.
  • Oliveira, Fabricio
  • Udeh-Momoh, Chinedu|||0000-0002-7357-4692
  • Lleó, Alberto|||0000-0002-2568-5478
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Pijnenburg, Yolande|||0000-0003-2464-1905
Frontotemporal dementia (FTD) covers a spectrum of neurodegenerative disorders with different phenotypes, genetic backgrounds, and pathological states. Its clinicopathological diversity challenges the diagnostic process and the execution of clinical trials, calling for specific diagnostic biomarkers of pathologic FTD types. There is also a need for biomarkers that facilitate disease staging, quantification of severity, monitoring in clinics and observational studies, and for evaluation of target engagement and treatment response in clinical trials. This review discusses current FTD biofluid-based biomarker knowledge taking into account the differing applications. The limitations, knowledge gaps, and challenges for the development and implementation of such markers are also examined. Strategies to overcome these hurdles are proposed, including the technologies available, patient cohorts, and collaborative research initiatives. Access to robust and reliable biomarkers that define the exact underlying pathophysiological FTD process will meet the needs for specific diagnosis, disease quantitation, clinical monitoring, and treatment development.